Biblioteca Humberto Rosselli Quijano
[artículo]
| Título : |
Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment |
| Tipo de documento: |
texto impreso |
| Autores: |
Sven Ulrich, Autor ; Sabine Neuhof, Autor ; Verena Braun, Autor |
| Fecha de publicación: |
2023 |
| Artículo en la página: |
pp. 210-219 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Antipsicóticos, Haloperidol, Compuestos de piridinio, Esquizofrenia. |
| Resumen: |
In an open clinical trial, serum concentrations of haloperidol pyridinium (CHP+) and reduced haloperidol pyridinium (CRHP+), as well as haloperidol (CH) and reduced haloperidol (CRH), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was monitored with the Brief Psychiatric Rating Scale (BPRS), and extrapyramidal adverse effects were assessed with the Extrapyramidal Symptom Rating Scale (EPS). |
| Link: |
./index.php?lvl=notice_display&id=31217 |
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 210-219
[artículo] Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment [texto impreso] / Sven Ulrich, Autor ; Sabine Neuhof, Autor ; Verena Braun, Autor . - 2023 . - pp. 210-219. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 210-219
| Palabras clave: |
Antipsicóticos, Haloperidol, Compuestos de piridinio, Esquizofrenia. |
| Resumen: |
In an open clinical trial, serum concentrations of haloperidol pyridinium (CHP+) and reduced haloperidol pyridinium (CRHP+), as well as haloperidol (CH) and reduced haloperidol (CRH), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was monitored with the Brief Psychiatric Rating Scale (BPRS), and extrapyramidal adverse effects were assessed with the Extrapyramidal Symptom Rating Scale (EPS). |
| Link: |
./index.php?lvl=notice_display&id=31217 |
|
